News

Scientists from the MRC Laboratory of Molecular Biology in Cambridge and University College London have discovered an essential feature of HIV that the virus uses to infect cells whilst avoiding detection by the immune system. This discovery presents a new drug target and the opportunity to re-evaluate existing treatments for HIV to improve their efficacy.

According to a new study, some bacteria, called fusobacteria, commonly found in the mouth, use a sugar-binding protein to stick to developing colorectal polyps and cancers.

Cancer cells kill blood vessel cells so that they can slip through the vascular wall and form metastases.

Collaboration sets out to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate bacterial strains.

High levels of fluorinated compounds have been linked to cancer, hormone disruption.

Acquisition to demonstrate the real-world effectiveness and value of biopharmaceutical products.

Scientists at Wageningen UR have developed a faster and more accurate method for the detection of drug use using hair.

New study illuminates structure of mystery protein.

Partnership aims to develop its GEN-1 Immuno-Oncology Therapy.

A method for “silencing” RNA that emerged from a University of Wisconsin—Madison spinoff company is in clinical trials in Europe, Asia and the United States against hepatitis B, an infection that can destroy the liver.